ClinicalTrials.gov
ClinicalTrials.gov Menu

Allergenic Effect of Ambrosia in Israel

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01413256
Recruitment Status : Unknown
Verified August 2011 by Rambam Health Care Campus.
Recruitment status was:  Not yet recruiting
First Posted : August 10, 2011
Last Update Posted : August 10, 2011
Sponsor:
Information provided by:
Rambam Health Care Campus

Brief Summary:

Background:

Respiratory allergic reaction causes great suffering to millions of people worldwide. One of the most known allergen- is the pollen from vegetation, ragweed. Genus Ambrosia Ambrosia belonged to the complex ragweed flowers are pollinated by the wind and the plant's male flowers produce large quantities of small grains of pollen and airborne over long distances and those causes allergic reactions. The plant blooms between June and October, creating a second wave after wave of allergy caused by spring blossoms.

This plant originated in North America has invaded many areas in Europe and in recent years, taking over large areas in Israel, Hula Valley and northern Acre Emek Hefer for a pen and layers to the south. After ragweed plants are based in particular they spread quickly and invade agricultural fields and significantly reduce the crop.

High allergenic ragweed is a health hazard to humans. Ragweed plant investigated many aspects of North America and Europe in recent decades and extensive literature on ambrosia, but this is the first time ragweed study focuses on Israel.

Working hypothesis and aims:

Goal of this study is to identify the existence and nature of the sensitivity distribution of ragweed in Israel.

Importance of research:

A. Ragweed allergen testing and comparing the effect of exposure to plants on the sensitivity of the allergic Israeli patients

B. The inclusion of ragweed allergen in the diagnostic and therapeutic panel


Condition or disease
Allergy Ambrosia Ragweed

Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Cohort
Study Start Date : October 2011
Estimated Primary Completion Date : December 2012
Estimated Study Completion Date : December 2012




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
respiratory allergic patients
Criteria

Inclusion Criteria:

  • respiratory allergic patients

Exclusion Criteria:

  • non respiratory allergic patients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01413256


Contacts
Contact: Eduardo Shahar, PI +972502061699 ed_shahar@rambam.health.gov.il

Sponsors and Collaborators
Rambam Health Care Campus

Responsible Party: EDUARDO SHAHAR, RAMBAM MEDICAL CENTER
ClinicalTrials.gov Identifier: NCT01413256     History of Changes
Other Study ID Numbers: 0015-11-RMB
First Posted: August 10, 2011    Key Record Dates
Last Update Posted: August 10, 2011
Last Verified: August 2011